Printed From BioPortfolio.com
EU nod for Shire’s longer-acting haemophilia A therapy
05:14 EST 15 Jan 2018 | PharmaTimes
Shire’s Adynovi has been approved for use in Europe for on-demand and prophylactic use in patients 12 years and older with the rare bleeding disorder haemophilia A.
Original Article: EU nod for Shire’s longer-acting haemophilia A therapy
